[1] 陈竺.全国第三次死因回顾抽样调查报告[J].北京:中国协和医科大学出版社,2008
[2] KARIO K, PICKERING T G, MATSUO T, et al. Stroke Prognosis and Abnormal Nocturnal Blood Pressure Falls in Older Hypertensives[J].Hypertension,2001,38(4):852-857.
[3] FAGARD R H, THIJS L, STAESSEN J A, et al. Night-day Blood Pressure Ratio and Dipping Pattern as Predictors of Death and Cardiovascular Events in Hypertension[J].J Hum Hypertens,2009,23(10):645-653.
[4] KARIO K, SAITO I, KUSHIRO T, et al. Morning Home Blood Pressure Is a Strong Predictor of Coronary Artery Disease:The HONEST Study[J].J Am Coll Cardiol,2016,67:1519-1527.
[5] MCMANUS R J, MANT J, FRANSSEN M, et al. Efficacy of Self-monitored Blood Pressure,with or without Telemonitoring,for Titration of Antihypertensive Medication (TASMINH4):an Unmasked Randomised Controlled Trial[J].Lancet,2018,391:949-959.
[6] ZHANG X, PATEL A, HORIBE H, et al. Cholesterol,Coronary Heart Disease,and Stroke in the Asia Pacific Region[J].International Journal of Epidemiology,2003,32 (4):563-572.
[7] SIPAHI I, SWAMINATHAN A, NATES A V, et al. Effect of Antihypertensive Therapy on Incident Stroke in Cohorts with Prehypertensive Blood Pressure Levels:A Meta-analysis of Randomized Controlled Trials[J].Stroke,2012,43(2):432-440.
[8] BRUNSTR M M, CARLBERG B. Association of Blood Pressure Lowering with Mortality and Cardiovascular Disease Across Blood Pressure Levels:A Systematic Review and Meta-analysis[J].JAMA Intern Med,2018,178(1):28-36.
[9] BECKETT N S, PETERS R, FLETCHER A E, et al.Treatment of Hypertension in Patients 80 Years of Age or Older[J].N Engl J Med,2008,3581887-98.
[10] STRUIJK E A, MAY A M, WEZENBEEK N L, et al. Adherence to Dietary Guidelines and Cardiovascular Disease Risk in the EPIC-NL Cohort.Int J Cardiol,2014,176:354-9.
[11] HUO Y, LI J, QIN X, et al. Efficacy of Folic Acid Therapy in Primary Prevention of Stroke Among Adults with Hypertension in China:the CSPPT Randomized Clinical Trial.JAMA,2015,313,1325-35.
[12] CHEN G J, YANG M S. The Effects of Calcium Channel Blockers in the Prevention of Stroke in Ddults with Hypertension:a Meta-analysis of Data from 273,543 Participants in 31 Randomized Controlled Rrials[J].PLoS One,2013,8:e57854.
[13] PSATY B M, LUMLEY T, FURBERG C D, et al. Health Outcomes Associated with Various Antihypertensive Therapies Used as First-line Agents:a Network Meta-analysis[J].JAMA,2003, 289:2534-44.
[14] MCALISTER F A. Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers are Beneficial in Normotensive Atherosclerotic Patients:a Collaborative Meta-analysis of Randomized Rrials[J].Eur Heart J,2012,33:505-14.
[15] PATEL A, MACMAHON S, CHALMERS J, et al.Effects of a Fixed Combination of Perindopril and Indapamide on Macrovascular and Microvascular Outcomes in Patients with Type 2 Diabetes Mellitus (the ADVANCE trial):a Randomised Controlled Trial[J].Lancet,2007,370:829-40.
[16] LONN E M, BOSCH J, LÓPEZ-JARAMILLO P, et al.Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease[J].N Engl J Med.2016,374(21):2009-20.
[17] ZHANG Y, ZHANG X, LIU L, et al.Is a Systolic Blood Pressure Target <140 mmHg Indicated in All Hypertensives? Subgroup Analyses of Findings from the Randomized FEVER trial.Eur Heart J,2011,32,1500-8.
[18] WRIGHT J J, WILLIAMSON J D, WHELTON P K, et al.A Randomized Trial of Intensive Versus Standard Blood-Pressure Control.N Engl J Med,2015,373,2103-16.
[19] YANG W, LU J, WENG J, et al.Prevalence of Diabetes Among Men and Women in China[J].N Engl J Med,2010,362(12):1090-1101.
[20] 国家卫生计生委疾病预防控制局.《中国居民营养与慢性病报告 2015》[J].人民卫生出版 社,2016
[21] KISSELA B M, KHOURY J, KLEINDORFER D, et al.Epidemiology of Ischemic Stroke in Patients with Diabetes:The Greater Cincinnati/Northern Kentucky Stroke Study[J].Diabetes Care,2005,28(2):355-359.
[22] BRAGG F, LI L, YANG L, et al.Risks and Population Burden of Cardiovascular Diseases Associated with Diabetes in China:A Prospective Study of 0.5 Million Adults.PLoS Med,2016,13(7):e1002026.
[23] GAEDE P, LUND-ANDERSEN H, PARVING H H, et al.Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes[J].N Engl J Med,2008,358(6):580-591.
[24] 中华医学会糖尿病学分会.中国 2 型糖尿病防治指南(2017 年版)[J].中华糖尿病杂志
[25] SARWAR N P, GAO S, SESHASAI R, et al.Diabetes Mellitus,Fasting Blood Glucose Concentration,and Risk of Vascular Disease:a Collaborative Meta-analysis of 102 Prospective Studies.Lancet,2010,375(9733):2215-2222.
[26] HUANG Y X, CAI W, MAI, et al.Association Between Prediabetes and Risk of Cardiovascular Disease and All Cause Mortality:Systematic Review and Meta-analysis.Bmj,2016,355:i5953.
[27] KAHN R, ALPERIN P, EDDY D, et al.Age at Initiation and Frequency of Screening to Detect Type 2 Diabetes:A Cost-effectiveness Analysis[J].Lancet,2010,375(9723):1365-1374.
[28] HERMAN W H, SMITH P J, THOMPSON T J ,et al.A New and Simple Questionnaire to Identify People at Increased Risk for Undiagnosed Diabetes[J].Diabetes Care,1995,18(3):382-387.
[29] CHOI S H, KIM T H, LIM S, et al.Hemoglobin A1c as a Diagnostic Tool for Diabetes Screening and New-onset Diabetes Prediction:A 6-year Community-based Prospective Study[J].Diabetes Care,2011,34(4):944-949.
[30] BUMRERRAJ S, KACZOROWSKI J, KESSOMBOON P, et al.Diagnostic Performance of 2 H postprandial Capillary and Venous Glucose as a Screening Test for Abnormal Glucose Tolerance[J].Prim Care Diabetes,2012,6(3):207-211.
[31] NORONHA R M, DAMACENO N, MURAMATU L H, et al.Importance of Screening with Oral glucose Tolerance Test for Early Diagnosis of Cystic Fibrosis-related Diabetes Mellitus[J].Pediatr Diabetes,2014,15(4):309-312.
[32] OIZUMI T, DAIMON M, JIMBU Y, et al.Impaired Glucose Tolerance is A Risk Factor for Stroke in A Japanese Sample–the Funagata Study[J].Metabolism,2008,57(3):333-338.
[33] RATNER R, GOLDBERG R, HAFFNER S, et al.Impact of Intensive Lifestyle and Metformin Therapy on Cardiovascular Disease Risk Factors in the Diabetes Prevention Program[J].Diabetes Care,2005,28(4):888-894.
[34] ISMAIL-BEIGI F, MOGHISSI E, TIKTIN M, et al.Individualizing Glycemic Targets in Type 2 Diabetes Mellitus:Implications of Recent Clinical Trials[J].Ann Intern Med,2011,154(8):554-559.
[35] BASTYR E J, STUART C A, BRODOWS R G, et al.Therapy Focused on Lowering Postprandial Glucose,Not Fasting Glucose,May be Superior for Lowering Hba1c.Loez Study group[J].Diabetes Care,2000,23(9):1236-1241.
[36] Effects of Ramipril on Cardiovascular and Microvascular Outcomes in People with Diabetes Mellitus:Results of the Hope Study and Micro-hope Substudy.Heart Outcomes Prevention Evaluation Study Investigators[J].Lancet,2000,355(9200):253-259.
[37] WACHTELL K, HORNESTAM B, LEHTO M, et al.Cardiovascular Morbidity and Mortality in Hypertensive Patients with a History of Atrial Fibrillation:The Losartan Intervention for End Point Reduction in Hypertension (life) study[J].J Am Coll Cardiol,2005,45(5):705-711.
[38] ISMAIL-BEIGI F, CRAVEN T, BANERJI M A, et al.Effect of Intensive Treatment of Hyperglycaemia on Microvascular Outcomes in Type 2 Diabetes:An Analysis of the Accord Randomised Trial[J].Lancet,2010,376(9739):419-430.
[39] CONTROL G, TURNBULL F M, ABRAIRA C, et al.Intensive Glucose Control and Macrovascular Outcomes in Type 2 Diabetes[J].Diabetologia,2009,52(11):2288-2298.
[40] WATKINS K, CONNELL C M. Measurement of Health-related Qol in Diabetes Mellitus[J].Pharmacoeconomics,2004,22(17):1109-1126.
[41] ROSSI M C, NICOLUCCI A, BARTOLO P, et al.Diabetes Interactive Diary:A new Telemedicine System Enabling Flexible Diet and Insulin Therapy While Improving Quality of Life:An Open-label,International,Multicenter,Randomized Study[J].Diabetes Care,2010,33(1):109-115.
[42] LAURENZI A, BOLLA A M, PANIGONI G, et al.Effects of Carbohydrate Counting on Glucose Control and Quality of Life Over 24 Weeks in Adult Patients with Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion:A Randomized,Prospective Clinical Trial (giocar)[J].Diabetes Care,2011,34(4):823-827.
[43] RICKHEIM P L, WEAVER T W, FLADER J L, et al.Assessment of Group Versus Individual Diabetes Education:A Randomized Study[J].Diabetes Care,2002,25(2):269-274.
[44] MILLER C K, EDWARDS L, KISSLING G, et al.Nutrition Education Improves Metabolic Outcomes Among Older Adults with Diabetes Mellitus:Results From a Randomized Controlled Trial[J].Prev Med,2002,34(2):252-259.
[45] AHMAD B, RAMADAS A, KIA F Q, et al. A Pilot Study:The Development of a Culturally Tailored Malaysian Diabetes Education Module (my-demo) Based on the Health Belief Bodel[J].BMC Endocr Disord,2014,14:31.
[46] GUO J, GUAN T, SHEN Y, et al.Lifestyle Factors and Gender-Specific Risk of Stroke in Adults with Diabetes Mellitus:A Case-Control Study[J].Stroke Cerebrovasc Dis,2018.27(7):1852-1860.
[47] Effect of Intensive Blood-glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34).UK Prospective Diabetes Study (UKPDS) Group.Lancet.1998.352(9131):854-65.
[48] WRIGHT A, BURDEN A C, PAISEY R B, et al.Sulfonylurea Inadequacy:Efficacy of Addition of Insulin Over 6 Years in Patients with Type 2 Diabetes in the UK.Prospective Diabetes Study (ukpds 57)[J].Diabetes Care,2002,25(2):330-336.
[49] BOWKER S L, MAJUMDAR S R, VEUGELERS P, et al.Increased Cancer-related Mortality for Patients with Type 2 Diabetes Who Use Sulfonylureas or Insulin[J].Diabetes Care,2006,29(2):254-258.
[50] BENNETT W L, MARUTHUR N M, SINGH S, et al.Comparative Effectiveness and Safety of Medications for Type 2 Diabetes:An Update Including New Drugs and 2-drug Combinations[J].Ann Intern Med,2011,154(9):602-613.
[51] COOPER-DEHOFF R M, GONG Y, HANDBERG E M, et al.Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients with Diabetes and Coronary Artery Disease[J].JAMA,2010,304(1):61-68.
[52] SLEIGHT P, REDON J, VERDECCHIA P, et al.Prognostic Value of Blood Pressure in Patients with High Vascular Risk in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial Study[J].J Hypertens,2009,27(7):1360-1369.
[53] BANGALORE S, KUMAR S, LOBACH I, et al.Blood Pressure Targets in Subjects with Type 2 Diabetes Mellitus/Impaired Fasting Glucose:Observations From Traditional and Bayesian Random-effects Meta-analyses of Randomized Trials[J].Circulation,2011,123(24):2799-2810,2799 p following 2810.
[54] COLLINS R, ARMITAGE J, PARISH S, et al.Mrc/Bhf Heart Protection Study of Cholesterol-lowering with Simvastatin in 5963 People with Diabetes:A Randomised Placebo-controlled Trial[J].Lancet,2003,361(9374):2005-2016.
[55] GROUP A S, GINSBERG H N, ELAM M B, et al.Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus[J].N Engl J Med,2010,362(17):1563-1574.
[56] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016 年修订 版)[J].中国循环杂志,2016,31(10):937-950.
[57] KURTH T, EVERETT B M, BURING J E, et al.Lipid Levels and the Risk of Ischemic Stroke in Women[J].Neurology,2007,68 (8):556-562.
[58] BAIGENT C, KEECH A, KEARNEY P M, et al.Efficacy and Safety of Cholesterol-lowering Treatment:Prospective Meta-analysis of Data from 90,056 Participants in 14 Randomised Trials of Statins[J].Lancet,2005,366(9493):1267-1278.
[59] STONE N J, ROBINSON J G, LICHTENSTEIN A H, et al.2013 Acc/aha Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults:A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2014,63(25 Pt B):2889-2934.
[60] JACOBSON T A, ITO M K, MAKI K C, et al.National Lipid Association Recommendations for Patient-centered Management of Dyslipidemia:Part 1–full Report[J].J Clin Lipidol,2015,9(2):129-169.
[61] TERAMOTO T, SASAKI J, ISHIBASHI S, et al.Executive Summary of the Japan Atherosclerosis Society (jas) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan -2012 version[J].J Atheroscler Thromb,2013,20(6):517-523.
[62] GRUNDY S M, STONE N J, BAILEY A L, et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/AD-A/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J].Journal of the American College of Cardiology,2019,73 (24):e285-e350.
[63] 中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管 病杂志,2007,35(05):390-419.
[64] RABAR S, HARKER M, O'FLYNN N, et al.Lipid Modification and Cardiovascular Risk Assessment for the Primary and Secondary prevention of cardiovascular disease:Summary of updated nice guidance[J].BMJ,2014,349:g4356.
[65] 胡大一.降低密度脂蛋白胆固醇是硬道理[J].中华心血管病杂志,2015,43(01):3-4. [66] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国脑血管病一级预 防指南 2015[J].中华神经科,2015,48(8):629-643.
[67] FORCE M, CATAPANO A L, GRAHAM I, et al.2016 esc/eas Guidelines for the Management of Dyslipidaemias:The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (esc) and European Atherosclerosis Society (eas) Developed with the Special Contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (eacpr)[J].Atherosclerosis,2016,253:281-344.
[68] NACI H, BRUGTS J J, FLEURENCE R, et al.Comparative Effects of Statins on Major Cerebrovascular Events:A Multiple-Treatments Meta-analysis of Placebo-controlled and Active-comparator Trials[J].QJM,2013,106(4):299-306.
[69] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南（2016 年修订 版）[J].中国循环杂志,2016,31 (10).
[70] LAROSA J C, GRUNDY S M, WATERS D D, et al.Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease[J].N Engl J Med,2005,352(14):1425-1435.
[71] SEVER P S, DAHLOF B, POULTER N R, et al.Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients Who have Average or Lower-than-average Cholesterol Concentrations,in the Anglo-scandinavian Cardiac Outcomes Trial–lipid Lowering Arm (ascot-lla):A Multicentre Randomised Controlled Trial[J].Lancet,2003,361(9364):1149-1158.
[72] EVERETT B M, GLYNN R J, MACFADYEN J G, et al.Rosuvastatin in the Prevention of Stroke Among Men and Women with Elevated Levels of C-reactive Protein:Justification for the Use of Statins in Prevention:An Intervention Trial Evaluating Rosuvastatin (jupiter)[J].Circulation,2010,121(1):143-150.
[73] SACCO R L, ADAMS R, ALBERS G, et al.Guidelines for Prevention of Stroke in Patients with Ischemic Stroke or Transient Ischemic Attack:A Statement for Healthcare Professionals from the American Heart Association/American Stroke Association Council on Stroke:Co-sponsored by the Council on Cardiovascular Radiology and Intervention:The American Academy of Neurology Affirms the Value of This Guideline[J].Circulation,2006,113(10):e409-449.
[74] Cardiogenic Brain Embolism.The Second Report of the Cerebral Embolism Task Force[J].Arch Neurol,1989,46(7):727-743.
[75] ARBOIX A, OLIVERES M, MASSONS J, et al.Early Differentiation of Cardioembolic from Atherothrombotic Cerebral Infarction:A Multivariate Analysis[J].Eur J Neurol,1999,6(6):677-683.
[76] DOUFEKIAS E, SEGAL A Z, KIZER J R. Cardiogenic and Aortogenic Brain Embolism[J].J Am Coll Cardiol,2008,51(11):1049-1059.
[77] PETERSEN P. Thromboembolic Complications in Atrial Fibrillation[J].Stroke,1990,21(1):4-13.
[78] FITZMAURICE D A, HOBBS F D, JOWETT S, et al.Screening Versus Routine Practice in Detection of Atrial Fibrillation in Patients Aged 65 or Over:Cluster Randomised Controlled Trial[J].BMJ,2007,335(7616):383.
[79] HOBBS F D, FITZMAURICE D A, MANT J, et al.A Randomised Controlled Trial and Cost-effectiveness Study of Systematic Screening (Targeted and Total Population Screening) Versus Routine Practice for the Detection of Atrial Fibrillation in People Aged 65 and Over.The Safe Study[J].Health Technol Assess,2005,9(40):iii-iv,ix-x,1-74.
[80] REIFFEL J A, VERMA A, KOWEY P R, et al.Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population:The REVEAL AF Study.JAMA Cardiol,2017,2(10):1120-1127.
[81] HALCOX, WAREHAM K, CARDEW A, et al.Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation:The REHEARSE-AF Study.Circulation,2017,136(19):1784-1794.
[82] Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation.Analysis of Pooled Data from Five Randomized Controlled Trials[J].Arch Intern Med,1994,154(13):1449-1457.
[83] KORNEJ J, HINDRICKS G, KOSIUK J, et al.Renal Dysfunction,Stroke Risk Scores (Chads2,Cha2ds2-vasc,and R2chads2),and the Risk of Thromboembolic Events After Catheter Ablation of Atrial Fibrillation:The Leipzig Heart Center af Ablation Registry[J].Circ Arrhythm Electrophysiol,2013,6(5):868-874.
[84] MASON P K, LAKE D E, DIMARCO J P, et al.Impact of the Cha2ds2-vasc Score on Anticoagulation Recommendations for Atrial Fibrillation[J].Am J Med,2012,125(6):603 e601-606.
[85] SERRANO R, MARTINEZ M A, ANDRES A, et al.Familial Mediterranean Fever and Acute Myocardial Infarction Secondary to Coronary Vasculitis[J].Histopathology,1998,33(2):163-167.
[86] OLESEN J B, TORP-PEDERSEN C, HANSEN M L, et al. The Value of the Cha2ds2-vasc Score for Refining Stroke Risk Stratification in Patients with Atrial Fibrillation with a Chads2 Score 0-1:A Nationwide Cohort Study[J].Thromb Haemost,2012,107(6):1172-1179.
[87] LIP G Y, NIEUWLAAT R, PISTERS R, et al. Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-based Approach:The Euro Heart Survey on Atrial Fibrillation[J].Chest,2010,137(2):263-272.
[88] CONNOLLY S J, EZEKOWITZ M D, YUSUF S,e t al.Dabigatran Versus Warfarin in Patients with Atrial Fibrillation[J].N Engl J Med,2009,361(12):1139-1151.
[89] GRANGER C B, ALEXANDER J H, MCMURRAY J J, et al.Apixaban Versus Warfarin in Patients with Atrial Fibrillation[J].N Engl J Med,2011,365(11):981-992.
[90] PATEL M R, MAHAFFEY K W, GARG J, et al.Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation[J].N Engl J Med,2011,365(10):883-891.
[91] AGUILAR M, HART R. Antiplatelet Therapy for Preventing Stroke in Patients with Non-valvular Atrial Fibrillation and No Previous History of Stroke or Transient Ischemic Attacks[J].Cochrane Database Syst Rev,2005(4):CD001925.
[92] HART R G, PEARCE L A, AGUILAR M I. Meta-analysis:Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation[J].Ann Intern Med,2007,146(12):857-867.
[93] European Heart Rhythm A,European Association for Cardio-Thoracic S,Camm AJ,et al.Guidelines for the Management of Atrial Fibrillation:The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (esc)[J].Eur Heart J,2010,31(19):2369-2429.
[94] MATCHAR B, JACOBSON D B, DOLOR R, et al.Effect of Home Testing of International Normalized Tatio on Clinical Events.N Engl j med,2010; 363:1608-1620][J].Kardiol Pol,2011,69(5):510-511.
[95] EZEKOWITZ M D, JAMES K E, RADFORD M J, et al.Initiating and Maintaining Patients on Warfarin Anticoagulation:The Importance of Monitoring[J].J Cardiovasc Pharmacol Ther,1999,4(1):3-8.
[96] HIRSH J, FUSTER V. Guide to Anticoagulant Therapy.Part 2:Oral Anticoagulants.American Heart Association[J].Circulation,1994,89(3):1469-1480.
[97] INVESTIGATORS A, CONNOLLY S J, POGUE J, et al.Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation[J].N Engl J Med,2009,360(20):2066-2078.
[98] INVESTIGATORS A, CONNOLLY S, POGUE J, et al.Clopidogrel Plus Aspirin Versus Oral Anticoagulation for Atrial Fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (active w):A Randomised Controlled Trial[J].Lancet,2006,367(9526):1903-1912.
[99] EIKELBOOM J W, WALLENTIN L, CONNOLLY S J, et al.Risk of Bleeding with 2 Doses of Dabigatran Compared with Warfarin in Older and Younger Patients with Atrial Fibrillation:An Analysis of the Randomized Evaluation of Long-term Anticoagulant Therapy (re-ly) trial[J].Circulation,2011,123(21):2363-2372.
[100] CONNOLLY S J, EIKELBOOM J, JOYNER C, et al.Apixaban in Patients with Atrial Fibrillation[J].N Engl J Med,2011,364(9):806-817.
[101] GIUGLIANO R P, RUFF C T, BRAUNWALD E, et al.Edoxaban Versus Warfarin in Patients with Atrial Fibrillation.N Engl J Med,2013.369(22):2093-2104.
[102] WINKELMAYER W C, LIU J, SETOGUCHI S, et al.Effectiveness and Safety of Warfarin Initiation in Older Hemodialysis Patients with Incident Atrial Fibrillation[J].Clin J Am Soc Nephrol,2011,6(11):2662-2668.
[103] PISTERS R, LANE D A, NIEUWLAAT R, et al.A Novel User-friendly Score (has-bled) to Assess 1-year Risk of Major Bleeding in Patients with Atrial Fibrillation:The Euro Heart Survey[J].Chest,2010,138(5):1093-1100.
[104] LIP G Y, FRISON L, HALPERIN J L, et al.Comparative Validation of A Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients with Atrial Fibrillation:The Has-bled (Hypertension,Abnormal Renal/Liver Function,Stroke,Bleeding History or Predisposition,Labile Inr,Elderly,Drugs/Alcohol Concomitantly) Score[J].J Am Coll Cardiol,2011,57(2):173-180.
[105] NAGANUMA M, SHIGA T, SATO K, et al.Clinical Outcome in Japanese Elderly Patients with Non-valvular Atrial Fibrillation Taking Warfarin:A Single-center Observational Study[J].Thromb Res,2012,130(1):21-26.
[106] GALLEGO P, ROLDAN V, TORREGROSA J M, et al.Relation of the Has-bled Bleeding Risk Score to Major Bleeding,Cardiovascular Events,and Mortality in Anticoagulated Patients with Atrial Fibrillation[J].Circ Arrhythm Electrophysiol,2012,5(2):312-318.
[107] HOLMES D R, REDDY V Y, TURI Z G, et al.Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation:A Randomised Non-inferiority Trial[J].Lancet,2009,374(9689):534-542.
[108] HOLMES D R, KAR S, PRICE M J, et al.Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients with Atrial Fibrillation Versus Long-term Warfarin Therapy:the PREVAIL Trial.J Am Coll Cardiol,2014,64(1):1-12.
[109] REDDY, DOSHI, KAR S, et al.5-Year Outcomes After Left Atrial Appendage Closure:From the PREVAIL and PROTECT AF Trials.J Am Coll Cardiol,2017,70(24):2964-2975.
[110] EAGLE K A, GUYTON R A, DAVIDOFF R, et al.Acc/Aha 2004 Guideline Update for Coronary Artery Bypass Graft Surgery:Summary Article:A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery)[J].Circulation,2004,110(9):1168-1176.
[111] HOGUE CW, MURPHY S F, SCHECHTMAN K B, et al.Risk Factors for Early or Delayed Stroke After Cardiac Surgery[J].Circulation,1999,100(6):642-647.
[112] AMARENCO P, DUYCKAERTS C, TZOURIO C, et al.The Prevalence of Ulcerated Plaques in the Aortic Arch in Patients with Stroke[J].N Engl J Med,1992,326(4):221-225.
[113] AMARENCO P, COHEN A, TZOURIO C, et al.Atherosclerotic Disease of the Aortic Arch and the Risk of Ischemic Stroke[J].N Engl J Med,1994,331(22):1474-1479.
[114] ANDERSON J L, ADAMS C D, ANTMAN E M, et al.Acc/Aha 2007 Guidelines for the Management of Patients with Unstable Angina/Non-st-elevation Myocardial Infarction:A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-st-elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians,the Society for Cardiovascular Angiography and Interventions,and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine[J].J Am Coll Cardiol,2007,50(7):e1-e157.
[115] Canadian Cardiovascular S,American Academy of Family P,American College of C,et al.2007 Focused Update of the Acc/Aha 2004 Guidelines for the Management of Patients with St-elevation Myocardial Infarction:A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2008,51(2):210-247.
[116] FUSTER V, RYDEN L E, CANNOM D S, et al.Acc/Aha/Esc 2006 Guidelines for the Management of Patients with Atrial Fibrillation-executive Summary:A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation)[J].Eur Heart J,2006,27(16):1979-2030.
[117] ANDREOTTI F, TESTA L, BIONDI-ZOCCAI G G, et al.Aspirin Plus Warfarin Compared to Aspirin Alone After Acute Coronary Syndromes:An Updated and Comprehensive Meta-analysis of 25,307 Patients[J].Eur Heart J,2006,27(5):519-526.
[118] HURLEN, ABDELNOOR M M, SMITH P, et al.Warfarin,Aspirin,or Both After Myocardial Infarction.New England Journal of Medicine,2002.347(13):969-974.
[119] BAUMER T, BUHRING N, SCHELLE T, et al.Nerve Ultrasound in Clinical Management of Carpal Tunnel Syndrome in Mucopolysaccharidosis[J].Dev Med Child Neurol,2016,58(11):1172-1179.
[120] PETTY G W, KHANDHERIA B K, MEISSNER I, et al.Population-based Study of the Relationship Between Patent Foramen Ovale and Cerebrovascular Ischemic Events[J].Mayo Clin Proc,2006,81(5):602-608.
[121] MEISSNER I, KHANDHERIA B K, HEIT J A, et al.Patent Foramen Ovale:Innocent or Guilty? Evidence from A Prospective Population-based Study[J].J Am Coll Cardiol,2006,47(2):440-445.
[122] DI T M, JIN Z, RUSSO C, et al.Patent Foramen Ovale,Subclinical Cerebrovascular Disease,and Ischemic Stroke in a Population-based Cohort[J].J Am Coll Cardiol,2013,62(1):35-41.
[123] ROACH G W, KANCHUGER M, MANGANO C M, et al.Adverse Cerebral Outcomes after Coronary Bypass Surgery.Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators[J].N Engl J Med,1996,335(25):1857-1863.
[124] LOH E, SUTTON M S, WUN C C, et al.Ventricular Dysfunction and the Risk of Stroke after Myocardial Infarction[J].N Engl J Med,1997,336(4):251-257.
[125] PFEFFER M A, BRAUNWALD E, MOYE LA, et al.Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction.Results of the Survival and Ventricular Enlargement Trial.The Save Investigators[J].N Engl J Med,1992,327(10):669-677.
[126] SHINDLER D M, KOSTIS J B, YUSUF S, et al.Diabetes Mellitus,a Predictor of Morbidity and Mortality in the Studies of Left Ventricular Dysfunction (Solvd) Trials and Registry[J].Am J Cardiol,1996,77(11):1017-1020.
[127] HOMMA S, THOMPSON J L, PULLICINO P M, et al.Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm[J].N Engl J Med,2012,366(20):1859-1869.
[128] CLELAND, FINDLAY J G F I, JAFRI S,et al. The Warfarin/Aspirin Study in Heart Failure (WASH):A Randomized Trial Comparing Antithrombotic Strategies for Patients with Heart Failure.American Heart Journal,2004.148(1):157-164
[129] MASSIE ,COLLINS B M J F, AMMON S E, et al.Randomized Trial of Warfarin,Aspirin,and Clopidogrel in Patients With Chronic Heart Failure The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial.Circulation,2009.119(12):1616-1624.
[130] BONOW R O, CARABELLO B A, CHATTERJEE K, et al.2008 Focused Update Incorporated into the Acc/Aha 2006 Guidelines for the Management of Patients with Valvular Heart Disease:A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease).Endorsed by the Society of Cardiovascular Anesthesiologists,Society for Cardiovascular Angiography and Interventions,and Society of Thoracic Surgeons[J].J Am Coll Cardiol,2008,52(13):e1-142.
[131] COULSHED N, EPSTEIN E J, MCKENDRICK C S, et al.Systemic Embolism in Mitral Valve Disease[J].Br Heart J,1970,32(1):26-34.
[132] CANNEGIETER S C, ROSENDAAL F R, BRIET E. Thromboembolic and Bleeding Complications in Patients with Mechanical Heart Valve Prostheses[J].Circulation,1994,89(2):635-641.
[133]国家卫生和计划生育委员会脑卒中筛查与防治工程委员会.卒中筛查与防治技术规范[J]. 中华神经科杂志,2014,47(03):199-203.
[134] HOWARD R A, ALDEA G S, SHAPIRA O M, et al.Papillary Fibroelastoma:Increasing Recognition of a Surgical Disease[J].Ann Thorac Surg,1999,68(5):1881-1885.
[135] LORENZ M W, MARKUS H S, BOTS M L, et al.Prediction of Clinical Cardiovascular Events with Carotid Intima-media Thickness:A Systematic Review and Meta-analysis[J].Circulation,2007,115(4):459-467.
[136] JIANG S, LIU R, HAN B. Relevance Analysis of Health Behaviors and Influencing Factors for Detection Rate of Carotid Atherosclerotic Plaque[J].Zhonghua Yi Xue Za Zhi,2014,94(23):1785-1787.
[137] MATHIESEN E B, JOHNSEN S H, WILSGAARD T, et al.Carotid Plaque Area and Intima-media Thickness in Prediction of First-ever Ischemic Stroke:A 10-year Follow-up of 6584 Men and Women:The Tromso Study[J].Stroke,2011,42(4):972-978.
[138] NISSEN S E, TUZCU E M, BREWER H B, et al.Effect of Acat Inhibition on the Progression of Coronary Atherosclerosis[J].N Engl J Med,2006,354(12):1253-1263.
[139] ABBOTT A L. Medical (nonsurgical) Intervention Alone is Now Best for Prevention of Stroke Associated with Asymptomatic Severe Carotid Stenosis:Results of a Systematic Review and Analysis[J].Stroke,2009,40(10):e573-583.
[140] MARQUARDT L, GERAGHTY O C, MEHTA Z, et al.Low Risk of Ipsilateral Stroke in Patients with Study[J].Stroke,2010,41(1):e11-17.
[141] HALLIDAYA, HARRISON M, HAYTER E, et al.10-year Stroke Prevention After Successful Carotid Endarterectomy for Asymptomatic Stenosis (acst-1):A Multicentre Randomised Trial[J].Lancet,2010,376(9746):1074-1084.
[142] MESCHIA J F, BUSHNELL C, BODEN-ALBALA B, et al.Guidelines for the Primary Prevention of Stroke:A Statement for Healthcare Professionals from the American Heart Association/American Stroke Association[J].Stroke,2014,45(12):3754-3832.
[143] ROTHWELL P M, GOLDSTEIN L B. Carotid Endarterectomy for Asymptomatic Carotid Stenosis:Asymptomatic Carotid Surgery Trial[J].Stroke,2004,35(10):2425-2427.
[144] HALLIDAYA, HARRISON M, HAYTER E, et al.10-year Stroke Prevention After Successful Carotid Endarterectomy for Asymptomatic Stenosis (acst-1):A Multicentre Randomised trial[J].Lancet,2010,376(9746):1074-1084.
[145] Endarterectomy for Asymptomatic Carotid artery Stenosis.Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.JAMA,1995.273(18):1421-1428.
[146] MESCHIA J F, BUSHNELL C, BODEN-ALBALA B, et al.Guidelines for the Primary Prevention of Stroke:A Statement for Healthcare Professionals from the American Heart Association/American Stroke Association[J].Stroke,2014,45(12):3754-3832.
[147] GURM H S, YADAV J S, FAYAD P, et al.Long-term Results of Carotid Stenting Versus Endarterectomy in High-risk Patients[J].N Engl J Med,2008,358(15):1572-1579.
[148] ECKSTEIN, REIFF H H T, RINGLEB P, et al.SPACE-2:A Missed Opportunity to Compare Carotid Endarterectomy,Carotid Stenting,and Best Medical Treatment in Patients with Asymptomatic Carotid Stenoses.Eur J Vasc Endovasc Surg,2016.51(6):761-765.
[149] BROOKS, MCCLURE W H R R, JONES M R, et al.Carotid Angioplasty and Stenting Versus Carotid Endarterectomy for Treatment of Asymptomatic Carotid Stenosis:a Randomized Trial in a Community Hospital.Neurosurgery,2004.54(2):318-324; discussion 324-315.
[150] SILVER, MACKEY F L A, CLARK W M, et al.Safety of Stenting and Endarterectomy by Symptomatic Status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST).Stroke,2011.42(3):675-680.
[151] ROSENFIELD, MATSUMURA K J S, CHATURVEDI S, et al.Randomized Trial of Stent Versus Surgery for Asymptomatic Carotid Stenosis.N Engl J Med,2016.374(11):1011-1020.
[152] MANNHEIM,D.and R.KARMELI,A Prospective Randomized Trial Comparing Endarterectomy to Stenting in Severe Asymptomatic Carotid Stenosis.J Cardiovasc Surg (Torino),2017.58(6):814-817.
[153] YUAN, ZHOU G S, WU W, et al.Carotid Artery Stenting Versus Carotid Endarterectomy for Treatment of Asymptomatic Carotid Artery Stenosis.Int Heart J,2018.
[154] LIAKISHEV AA.Protected Carotid-Artery Stenting Versus Endarterectomy in High-Risk Patients.Results of SAPPHIRE trial.Kardiologiia,2004.44(12):76. [155] FEIGIN V, PARAG V, LAWES C M M, et al.Smoking and Elevated Blood Pressure are the Most Important Risk Factors for Subarachnoid Hemorrhage in the Asia-Pacific Region:an Overview of 26 Cohorts Involving 306,620 Participants[J].Stroke,2005,36:1360-5.
[156] KELLY, GU T N D, CHEN J, et al.Cigarette Smoking and Risk of Stroke in the Chinese Adult Population.Stroke,2008.39(6):1688-1693.
[157] 申倩,祝楠波,余灿清 等,中国成年人吸烟与心血管疾病发病风险的关联及其性别差异分 析.中华流行病学杂志,2018.39(1):8-15.
[158] MARKIDAN, COLE J J W, CRONIN C A, et al.Smoking and Risk of Ischemic Stroke in Young Men.Stroke,2018.49(5):1276-1278.
[159] LV J, YU C, GUO Y, et al.Adherence to Healthy Lifestyle and Cardiovascular Diseases in the Chinese Population.J Am Coll Cardiol,2017.69(9):1116-1125.
[160] WANNAMETHEE, SHAPER S G A G, WHINCUP P H, et al.Smoking Cessation and the Risk of Stroke in Middle-aged men.Jama,1995.274(2):155-160.
[161] HE, LAM Y T H, JIANG B, et al.Passive Smoking and Risk of Peripheral Arterial Disease and Ischemic Stroke in Chinese Women Who Never Smoked.Circulation,2008.118(15):1535-1540.
[162] FISCHER,F.and A.KRAEMER,Meta-analysis of the AssociationSmoke Exposure and Ischaemic Heart Diseases,COPD and Stroke.BMC Public Health,2015.15:1202.
[163] MALEK, CUSHMAN A M M, LACKLAND D T, et al.Secondhand Smoke Exposure and Stroke:The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.Am J Prev Med,2015.49(6):e89-97.
[164] HERMAN P M, WALSH M E. Hospital Admissions for Acute Myocardial Infarction,Angina,Stroke,and Asthma After Implementation of Arizona's Comprehensive Statewide Smoking Ban.Am J Public Health,2011.101(3):491-496.
[165] STEAD, PERERA L F R, BULLEN C, et al.Nicotine Replacement Therapy for Smoking Cessation.Cochrane Database Syst Rev,2012.11:Cd000146.
[166] MILLS, WU E J P, LOCKHART I, et al.Comparisons of High-Dose and Combination Nicotine Replacement Therapy,Varenicline,and Bupropion for Smoking Cessation:a Systematic Review and Multiple Treatment Meta-Analysis.Ann Med,2012.44(6):588-597.
[167] BAKER C L G.PIETRI, A cost-effectiveness Analysis of Varenicline for Smoking Cessation Using Data from the EAGLES Trial.Clinicoecon Outcomes Res,2018.10:67-74[171] Gill JS,Zezulka AV,Shipley MJ,et al.Stroke and Alcohol Consumption[J].N Engl J Med,1986,315(17):1041-1046.
[168] GILL J S, ZEZULKA A V, SHIPLEY M J, et al.Stroke and Alcohol Consumption[J].N Engl J Med,1986,315(17):1041-1046.
[169] HILLBOM M, NUMMINEN H, JUVELA S. Recent Heavy Drinking of Alcohol and Embolic Stroke[J].Stroke,1999,30(11):2307-2312.
[170] BERGER K, AJANI U A, KASE C S, et al.Light-to-moderate Alcohol Consumption and Risk of Stroke Among U.S.Male Physicians[J].N Engl J Med,1999,341(21):1557-1564.
[171] BAZZANO L A, GU D, REYNOLDS K, et al.Alcohol Consumption and Risk for Stroke Among cChinese Men[J].Ann Neurol,2007,62(6):569-578.
[172] REYNOLDS K, LEWIS B, NOLEN J D, et al.Alcohol Consumption and Risk of Stroke:A Meta-analysis[J].JAMA,2003,289(5):579-588.
[173] MCGUIRE S U S. Department of Agriculture and U.S.Department of Health and Human Services,Dietary Guidelines for Americans,2010.7th Edition,Washington,dc:U.S.Government Printing Office,January 2011[J].Adv Nutr,2011,2(3):293-294.
[174] O'DONNELL, CHIN M J S L, RANGARAJAN S, et al.Global and Regional Effects of Potentially Modifiable Risk Factors Associated with Acute Stroke in 32 Countries (INTERSTROKE):a Case-control Study.Lancet,2016.388(10046):761-775.
[175] Alcohol use and Burden for 195 Countries and Territories,1990-2016:Asystematic Analysis for the Global Burden of Disease Study 2016[J].The Lancet,2018 Sep 22;392(10152):1015-1035.
[176] MILLWOOD I Y, WALTERS R G, MEI X W, et al.Conventional and Genetic Evidence on Alcohol and Vascular Disease Aetiology:a Prospective Study of 500 000 Men and Women in China.Lancet.2019 May 4;393(10183):1831-1842.
[177] BENNETT, DU D A H, CLARKE R, et al.Association of Physical Activity With Risk of Major Cardiovascular Diseases in Chinese Men and Women.JAMA Cardiol,2017.2(12):1349-1358.
[178] SMITH P J, BLUMENTHAL J A, HOFFMAN B M, et al.Aerobic Exercise and Neurocognitive Performance:A Meta-analytic Review of Randomized Controlled Trials[J].Psychosom Med,2010,72(3):239-252.
[179] COTMAN C W, BERCHTOLD N C, CHRISTIE L A. Exercise Builds Brain Health:Key Roles of Growth Factor Cascades and Inflammation[J].Trends Neurosci,2007,30(9):464-472.
[180] WILLEY, MOON J Z Y P, PAIK M C, et al.Lower Prevalence of Silent Brain Infarcts in the Physically Active:the Northern Manhattan Study.Neurology,2011.76(24):2112-2118.
[181] AREM, MOORE H S C, PATEL A, et al.Leisure Time Physical Activity and Mortality:a Detailed Pooled Analysis of the Dose-response Relationship.JAMA Intern Med,2015.175(6):959-967.
[182] LEE, PATE D C R R, LAVIE C J, et al.Leisure-time Running Reduces All-cause and Cardiovascular Mortality Risk.J Am Coll Cardiol,2014.64(5):472-481.
[183] STRATH, KAMINSKY S J L A, AINSWORTH B E, et al.Guide to the Assessment of Physical Activity:Clinical and Research Applications:a Scientific Statement from the American Heart Association.Circulation,2013.128(20):2259-2279.
[184] LOBELO, ROHM Y, SALLIS R, et al.Routine Assessment and Promotion of Physical Activity in Healthcare Settings:A Scientific Statement From the American Heart Association.Circulation,2018,137(18):e495-e522.
[185] HU F B, STAMPFER M J, COLDITZ G A, et al.Physical Activity and Risk of Stroke in Women[J].JAMA,2000,283(22):2961-2967.
[186] LEE C D, FOLSOM A R, BLAIR S N. Physical Activity and Stroke risk:A meta-analysis[J].Stroke,2003,34(10):2475-2481.
[187] ZHANG X, SHU X O, GAO Y T, et al.General and Abdominal Adiposity and Risk of Stroke in Chinese Women[J].Stroke,2009,40(4):1098-1104.
[188] JENSEN M D, RYAN D H, APOVIAN C M, et al.2013 Aha/Acc/Tos Guideline for the Management of Overweight and Obesity in Adults:A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society[J].J Am Coll Cardiol,2014,63(25 Pt B):2985-3023.
[189] WANG, LIU C Y, YANG Q, et al.Body Mass Index and Risk of Total and Type-specific Stroke in Chinese Adults:Results from A Longitudinal Study in China.Int J Stroke,2013,8(4):245-250.
[190] STRAZZULLO, D'ELIA P L, CAIRELLA G, et al.Excess Body Weight and Incidence of Stroke:Meta-analysis of Prospective Studies with 2 Million Participants.Stroke,2010,41(5):e418-426.
[191] 赵连成,武阳丰,周北凡,等.体质指数与冠心病、脑卒中发病的前瞻性研究.中华心血管病 杂志,2002,30(7):430-433.
[192] TOSS, WIKLUND F P, FRANKS P W, et al.Abdominal and Gynoid Adiposity and the Risk of Stroke.International Journal of Obesity,2011,35(11):1427-1432.
[193] ZAHN, LINSEISEN K J, HEIER M, et al.Body fat Distribution and Risk of Incident Ischemic Stroke in Men and Women Aged 50 to 74 Years from the General Population.The KORA Augsburg Cohort study.Plos One,2018,13(2):e0191630.
[194] NETER J E, STAM B E, KOK F J, et al.Influence of Weight Reduction on Blood Pressure:A Meta-analysis of Randomized Controlled Trials[J].Hypertension,2003,42(5):878-884.
[195] STRAZZULLO P, D'ELIA L, CAIRELLA G, et al.Excess Body Weight and Incidence of Stroke:Meta-analysis of Prospective Studies with 2 Million Participants[J].Stroke,2010,41(5):e418-426.
[196] SJOSTROM L. Review of the Key Results from the Swedish Obese Subjects (Sos) Trial – a Prospective Controlled Intervention Study of Bariatric Surgery[J].J Intern Med,2013,273(3):219-234.
[197] ECKEL R H, JAKICIC J M, ARD J D, et al.2013 Aha/Acc Guideline on Lifestyle Management to Reduce Cardiovascular Risk:A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2014,63(25 Pt B):2960-2984.
[198] ESTRUCH, ROS R E, SALAS-SALVADO J, et al.Primary Prevention of Cardiovascular Disease with a Mediterranean Diet.N Engl J Med,2013.368(14):1279-1290.
[199] CHANG H Y, HU Y W, YUE C S, et al.Effect of Potassium-enriched Salt on Cardiovascular Mortality and Medical Expenses of Elderly Men[J].Am J Clin Nutr,2006,83(6):1289-1296.
[200] HE, OGDEN J L G, VUPPUTURI S, et al.Dietary Sodium Intake and Subsequent Risk of Cardiovascular Disease in Overweight Adults.Jama,1999,282(21):2027-2034.
[201] NAGATA,TAKATSUKA C N,SHIMIZU N,et al.Sodium Intake and Risk of Death from Stroke in Japanese Men and Women.Stroke,2004,35(7):1543-1547.
[202] LI X Y, CAI X L ,BIAN P D, et al.High Salt Intake and Stroke:Meta-analysis of the Epidemiologic Evidence.CNS Neurosci Ther,2012,18(8):691-701.
[203] D'ELIA, BARBA L G, CAPPUCCIO F P, et al.Potassium Intake,Stroke,and Cardiovascular Disease a Meta-analysis of Prospective Studies.J Am Coll Cardiol,2011.57(10):1210-1219.
[204] 中国肥胖问题工作组.中国成人超重和肥胖症预防与控制指南(节录).营养学 报,2004,26(1):1-4.
[205] KOKUBO Y, ISO H, ISHIHARA J, et al.Association of Dietary Intake of Soy,Beans,and Isoflavones with Risk of Cerebral and Myocardial Infarctions in Japanese Populations:The Japan Pblic Health Center-based (Jphc) Study Cohort i[J].Circulation,2007,116(22):2553-2562.
[206] WILDMAN, MCGINN R P A P, LIN J, et al.Cardiovascular Disease Risk of Abdominal Obesity vs.Metabolic Abnormalities.Obesity (Silver Spring),2011,19(4):853-860.
[207] Clinical Guidelines on the Identification,Evaluation,and Treatment of Overweight and Obesity in Adults–The Evidence Report.National Institutes of Health.Obes Res,1998,6 Suppl 2:51s-209s.
[208] JOSHIPURA, ASCHERIO K J A, MANSON J E, et al.Fruit and Vegetable Intake in Relation to Risk of Ischemic Stroke.Jama,1999,282(13):1233-1239.
[209] WILDMAN, MCGINN R P A P, LIN J, et al.Cardiovascular Disease Risk of Abdominal Obesity vs.Metabolic Abnormalities.Obesity (Silver Spring),2011,19(4):853-860.
[210] HE, SONG K Y, DAVIGLUS M L, et al.Fish Consumption and Incidence of Stroke:a Meta-analysis of Cohort Studies.Stroke,2004,35(7):1538-1542.
[211] ADELBORG, SZEPLIGETI K S K, HOLLAND-BILL L, et al.Migraine and Risk of Cardiovascular Diseases:Danish Population Based Matched Cohort Study.Bmj,2018,360:k96. k96
[212] CHAMPALOUX, TEPPER S W N K, MONSOUR M, et al.Use of Combined Hormonal Contraceptives Among Women with Migraines and Risk of Ischemic Stroke.Am J Obstet Gynecol,2017,216(5):489,e481-489;e487.
[213] ANNA V, WOODWARD M. Frequency of Migraine and the Risk of Cardiovascular Disease for Women:Limited Evidence of an Association[J].Womens Health (Lond),2009,5:625-8.
[214] PIETROBON D, MOSKOWITZ M A. Pathophysiology of Migraine[J].Annu Rev Physiol,2013,75:365-391.
[215] WEST B H, NOUREDDIN N, MAMZHI Y, et al.Frequency of Patent Foramen Ovale and Migraine in Patients With Cryptogenic Stroke[J].Stroke,2018,49:1123-1128.
[216] MARTINEZ-SANCHEZ P, MARTINEZ-MARTINEZ M, FUENTES B, et al.Migraine and Hypercoagulable States in Ischemic Stroke[J].Cephalalgia,2011,31(16):1609-1617.
[217] TIETJEN G E.The Risk of Stroke in Patients with Migraine and Implications for Migraine Management[J].CNS Drugs,2005,19(8):683-692.
[218] ELWOOD P, HACK M, PICKERING J, et al.Sleep Disturbance,Stroke,and Heart Disease Events:Evidence from the Caerphilly Cohort[J].J Epidemiol Community Health,2006,60(1):69-73.
[219] MUNOZ R, DURAN-CANTOLLA J, MARTINEZ-VILA E, et al.Severe Sleep Apnea and Risk of Ischemic Stroke in the Elderly[J].Stroke,2006,37(9):2317-2321.
[220] CHANG C C, CHUANG H C, LIN C L, et al.High Incidence of Stroke in Young Women with Sleep Apnea Syndrome[J].Sleep Med,2014,15:410-4.
[221] YAGGI H K, CONCATO J, KERNAN W N, et al.Obstructive Sleep Apnea as a Risk Factor for Stroke and Death[J].N.Engl.J.Med.2005,353:2034-41.
[222] REDLINE S, YENOKYAN G, GOTTLIEB D J, et al.Obstructive Sleep Apnea-Hypopnea and Incident Stroke:the Sleep Heart Health Study[J].Am.J.Respir.Crit.Care Med,2010,182:269-77.
[223] GILES T L, LASSERSON T J, SMITH B H, et al.Continuous Positive Airways Pressure for Obstructive Sleep Apnoea in Adults[J].Cochrane Database Syst Rev,2006(3):CD001106.
[224] MCNEIL J J, WOLFE R, WOODS R L, et al.Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly[J].N.Engl.J.Med,2018,379:1509-1518.
[225] MORA S, MANSON J E. Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease:Advances in Diagnosis and Treatment[J].JAMA Intern Med,2016,176:1195-204.
[226] GAZIANO J M, BROTONS C, COPPOLECCHIA R, et al.Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE):a Randomised,Double-Blind,Placebo-Controlled Trial[J].Lancet,2018,392:1036-1046.
[227] ZHENG S L, RODDICK A J. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events:A Systematic Review and Meta-analysis[J].JAMA,2019,321:277-287.
[228] RIDKER P M, COOK N R, LEE I M, et al.A randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women[J].N Engl J Med,2005,352(13):1293-1304.
[229] XIE M, SHAN Z, ZHANG Y, et al.Aspirin for Primary Prevention of Cardiovascular Events:Meta-analysis of Randomized Controlled Trials and Subgroup Analysis by Sex and Diabetes Status[J].PLoS One,2014,9(10):e90286.
[230] OGAWA H, NAKAYAMA M, MORIMOTO T, et al.Low-dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients with Type 2 Diabetes:A Randomized Controlled Trial[J].JAMA,2008,300(18):2134-2141.
[231] SAITO Y, OKADA S, OGAWA H, et al.Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus:10-Year Follow-Up of a Randomized Controlled Trial[J].Circulation,2017,135:659-670.
[232] ASCEND Study Collaborative Group,Bowman L,Mafham M et al.Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus[J].N.Engl.J.Med,2018,379:1529-1539.
[233] Kunutsor S K,Seidu S,Khunti K,Aspirin for Primary Prevention of Cardiovascular and All-Cause Mortality Events in Diabetes:Updated Meta-analysis of Randomized Controlled Trials[J].Diabet.Med,2017,34:316-327.
[234] HANSSON L, ZANCHETTI A ,CARRUTHERS S G, et al.Effects of Intensive Blood-Pressure Lowering and Low-Dose Aspirin in Patients with Hypertension:Principal Results of the Hypertension Optimal Treatment (Hot) Randomised Trial.Hot Study Group[J].Lancet,1998,351(9118):1755-1762.
[235] JARDINE M J, NINOMIYA T, PERKOVIC V, et al.Aspirin is Beneficial in Hypertensive Patients with Chronic Kidney Disease:a Post-Hoc Subgroup Analysis of a Randomized Controlled Trial[J].J.Am.Coll.Cardiol,2010,56:956-65.
[236] MAJOR R W, OOZEERALLY I, DAWSON S, et al.Aspirin and cCardiovascular Primary Prevention in Non-endstage Chronic Kidney Disease:A Meta-Analysis[J].Atherosclerosis,2016,251:177-182.
[237] HAN L, WU Q, WANG C, et al.Homocysteine,Ischemic Stroke,and Coronary Heart Disease in Hypertensive Patients:A Population-Based,Prospective Cohort Study[J].Stroke,2015,46(7):1777-1786.
[238] SHOAMANESH A, PREIS S, BEISER A, et al.Circulating Biomarkers and Incident Ischemic Stroke in the Framingham Offspring Study[J].Neurology,2016,87(12):1206-1211.
[239] WANG X, QIN X, DEMIRTAS H, et al.Efficacy of Folic Acid Supplementation in Stroke Prevention:A Meta-Analysis[J].Lancet,2007,369(9576):1876-1882.
[240] TOOLE J F, MALINOW M R, CHAMBLESS L E, et al.Lowering Homocysteine in Patients with iIschemic Stroke to Prevent Recurrent Sroke,Myocardial Infarction,and Death:The Vitamin Intervention for Stroke Prevention (Visp) Randomized Controlled Trial[J].JAMA,2004,291(5):565-575.
[241] BONAA K H, NJOLSTAD I, UELAND P M, et al.Homocysteine Lowering and Cardiovascular Events Ffter Acute Myocardial Infarction[J].N Engl J Med,2006,354(15):1578-1588.
[242] SAPOSNIK G, RAY J G, SHERIDAN P, et al.Homocysteine-Lowering Therapy and Stroke Risk,Severity,and Disability:Additional fFindings from the hope 2 Trial[J].Stroke,2009,40(4):1365-1372.
[243] GALAN P, KESSE-GUYOT E, CZERNICHOW S, et al.Effects of b Vitamins and Omega 3 Fatty Acids on Cardiovascular Diseases:A Randomised Placebo Controlled Trial[J].BMJ,2010,341:c6273.
[244] HANKEY G J, EIKELBOOM J W, YI Q, et al.Antiplatelet Therapy and the Effects of b Vitamins in Patients with Previous Stroke or Transient Ischaemic Attack:A Post-hoc Subanalysis of Vitatops,a Randomised,Placebo-Controlled Trial[J].Lancet Neurol,2012,11(6):512-520.
[245] HUO Y, LI J, QIN X, et al.Efficacy of Folic Acid Therapy in Primary Prevention of Stroke Among Adults with Hypertension in China:The Csppt Randomized ClinicaTrial[J].JAMA,2015,313(13):1325-1335.
[246] LI Y, HUANG T, ZHENG Y, et al.Folic Acid Supplementation and the Risk of Cardiovascular Diseases:A Meta-Analysis of Randomized Controlled Trials[J].J Am Heart Assoc,2016,5(8).
[247] MARTÍ-CARVAJAL A J,SOL I, LATHYRIS D, et al.Homocysteine-Lowering Interventions for Preventing Cardiovascular Events[J].Cochrane Database Syst Rev,2017,8:CD006612.
